Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James's University Hospital Leeds, Leeds, UK, provides us an insight into the future of treatments for chronic lymphocytic leukemia (CLL), namely the combinations of novel agents such as ibrutinib and venetoclax with chemotherapy, CAR T-cells and next-generation BTK inhibitors and other novel agents that may exert less toxicity on patients compared to previous drugs. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
